233 related articles for article (PubMed ID: 19694740)
1. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
Keskitalo JE; Kurkinen KJ; Neuvonen M; Backman JT; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2009 Aug; 68(2):207-13. PubMed ID: 19694740
[TBL] [Abstract][Full Text] [Related]
2. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
3. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
Keskitalo JE; Pasanen MK; Neuvonen PJ; Niemi M
Pharmacogenomics; 2009 Oct; 10(10):1617-24. PubMed ID: 19842935
[TBL] [Abstract][Full Text] [Related]
4. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
Niemi M; Pasanen MK; Neuvonen PJ
Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
[TBL] [Abstract][Full Text] [Related]
5. CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers.
Zhou Q; Ruan ZR; Yuan H; Zeng S
Arzneimittelforschung; 2012 Nov; 62(11):519-24. PubMed ID: 22941809
[TBL] [Abstract][Full Text] [Related]
6. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.
Keskitalo JE; Kurkinen KJ; Neuvoneni PJ; Niemi M
Clin Pharmacol Ther; 2008 Oct; 84(4):457-61. PubMed ID: 19238649
[TBL] [Abstract][Full Text] [Related]
7. Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren.
Tapaninen T; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2010 Sep; 66(9):865-70. PubMed ID: 20496145
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Neuvonen PJ; Backman JT; Niemi M
Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
[TBL] [Abstract][Full Text] [Related]
9. More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.
Robertsen I; Asberg A; Granseth T; Vethe NT; Akhlaghi F; Ghareeb M; Molden E; Reier-Nilsen M; Holdaas H; Midtvedt K
Transplantation; 2014 Jun; 97(12):1266-71. PubMed ID: 24521776
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
11. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
[TBL] [Abstract][Full Text] [Related]
12. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.
Aquilante CL; Wempe MF; Sidhom MS; Kosmiski LA; Predhomme JA
Eur J Clin Pharmacol; 2013 Jul; 69(7):1401-9. PubMed ID: 23407853
[TBL] [Abstract][Full Text] [Related]
13. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
[TBL] [Abstract][Full Text] [Related]
14. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
[TBL] [Abstract][Full Text] [Related]
15. The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males.
Lou XY; Zhang W; Wang G; Hu DL; Guo D; Tan ZR; Zhou HH; Chen Y; Bao HH
Pharmazie; 2014 Oct; 69(10):775-9. PubMed ID: 25985569
[TBL] [Abstract][Full Text] [Related]
16. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
17. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Hoffman KB; Kraus C; Dimbil M; Golomb BA
PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
[TBL] [Abstract][Full Text] [Related]
18. Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers.
Jensen BP; Roberts RL; Vyas R; Bonke G; Jardine DL; Begg EJ
Br J Clin Pharmacol; 2012 Apr; 73(4):619-28. PubMed ID: 21999196
[TBL] [Abstract][Full Text] [Related]
19. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
